Revolutionizing Cancer Treatment: Halda Therapeutics Secures $126M in Series B Funding for Breakthrough Precision Medicines

Halda Therapeutics is thrilled to announce that we have successfully raised $126 million in our latest funding round, an investment that underscores the confidence our partners have in our innovative approach to oncology. Founded by esteemed Yale scientist Professor Craig Crews, Halda is at the forefront of developing RIPTAC™ therapeutics—a groundbreaking drug modality designed to combat cancer. Unlike traditional cancer therapies that often target common oncogenic drivers, RIPTAC therapeutics utilize a unique ‘hold and kill’ mechanism to selectively target cancer cells. By bringing together two proteins in a tightly controlled manner, these therapeutics induce cell death by disrupting critical functions essential for tumor survival. The funds raised will be pivotal in advancing our pipeline of RIPTAC therapeutics aimed at treating major cancer types, particularly for patients grappling with drug-resistant cancers. This funding will also facilitate further research and development of our proprietary platform technology, fueling our mission to invent new and effective precision medicines. As a bold biotech company located in Science Park, New Haven, CT, we thrive on collaboration and creativity, continually pushing the boundaries of drug discovery. Our dedicated team believes that with the upcoming funding, we can transform the landscape of cancer treatment and significantly improve outcomes for patients who currently have limited options. We are excited about what the future holds and are committed to our vision of delivering novel therapies that address the unmet needs of cancer patients worldwide.